Abstract
As physicians how do we counsel our patients with clinically isolated syndrome (CIS) when they ask, 'what is the benefit of injecting disease-modifying agents (DMAs) over many years? What disability will they prevent in my future?' In this debate, we will provide three core points supporting the concept that a watchful waiting approach (annual neurological evaluation and magnetic resonance imaging of the head (with gadolinium) at least for the first few years after diagnosis) for most patients with CIS represents appropriate medical care.
Original language | English (US) |
---|---|
Pages (from-to) | 391-393 |
Number of pages | 3 |
Journal | Multiple Sclerosis Journal |
Volume | 18 |
Issue number | 4 |
DOIs | |
State | Published - Apr 2012 |
Keywords
- beta-interferon
- demyelination
- disease-modifying therapies
- glatiramer acetate
- multiple sclerosis
- outcome measurement
ASJC Scopus subject areas
- Neurology
- Clinical Neurology